肝细胞癌相关抗原特异性T淋巴细胞的研究进展

侯玉丽; 张永宏; 赵艳

doi:10.3969/j.issn.1001-5256.2016.06.048

肝细胞癌相关抗原特异性T淋巴细胞的研究进展

DOI: 10.3969/j.issn.1001-5256.2016.06.048

1. 首都医科大学附属北京佑安医院临床检验中心
2. 首都医科大学附属北京佑安医院生物信息中心

基金项目:

首都医科大学基础临床合作基金(1150170804)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1296
- HTML全文浏览量: 25
- PDF下载量: 330
- 被引次数: 0
出版历程
- 出版日期: 2016-06-20

Immunological characteristics of tumor antigen specific T cells and their possible mechanisms in hepatocellular carcinoma

Research funding:

摘要

摘要: 肝细胞癌（HCC）是世界范围的一个主要卫生问题,其发病率逐年上升,且早期诊断率较低,晚期HCC的生存率低,因此HCC的诊断和治疗引起了广泛关注,其中肿瘤特异性淋巴细胞免疫在其中发挥了重要作用。阐述了甲胎蛋白、磷脂酰肌醇蛋白多糖3、NY-ESO-1、SSX-2、黑色素抗原基因A、端粒酶反转录酶和肝癌相关抗原-519/靶蛋白xklp-2等HCC相关抗原特异性T淋巴细胞免疫特征,并从调节性T淋巴细胞、髓源性抑制细胞、抗原的递呈和处理、抑制性受体和CD4+T淋巴细胞方面分析了影响抗原特异性T淋巴细胞免疫的可能机制。通过研究HCC相关抗原特异性T淋巴细胞的免疫反应,从而对HCC的免疫治疗提供新的方向和治疗靶点。
- 癌,肝细胞 /
- 抗原,肿瘤 /
- T淋巴细胞 /
- 综述
Abstract: Hepatocellular carcinoma(HCC) is a major health problem around the world and its morbidity is increasing year by year.HCC has a low rate of early diagnosis and advanced HCC has a low survival rate.Therefore,the diagnosis and treatment of HCC has attracted great attention,and tumor specific T cell immunity plays an important role in it.This article describes the immunological characteristics of seven HCC- associated antigen specific T cells,i.e.,alpha fetal protein,phosphatidylinositol proteoglycan- 3,NY- ESO- 1,SSX- 2,melanoma antigen gene A,telomerase reverse transcriptase,and HCC- associated antigen- 519 / target protein xklp- 2,and analyzes the possible mechanisms which affect antigen specific T cell immunity from the aspects of regulatory T cells,myeloid- derived suppressor cells,antigen presenting and processing,inhibitory receptors,and CD4+T cells.
- carcimoma /
- hepatocellular /
- antigen /
- neoplasm

HTML全文

参考文献(36)

[1]LAFARO KJ,DEMIRJIAN AN,PAWLIK TM.Epidemiology of hepatocellular carcinoma[J].Surg Oncol Clin N Am,2015,24(1):1-17.

[2]LIN CL,KAO JH.Risk stratification for hepatitis B viru related hepatocellular carcinoma[J].J Gastroenterol Hepatol,2013,28(1):10-17.

[3]GOH GB,CHANG PE,TAN CK,et al.Changing epidemiology of hepatocellular carcinoma in Asia[J].Best Pract Res Clin Gastroenterol,2015,29(6):919-928.

[4]DAVILA JA,KRAMER JR,DUAN Z,et al.Referral and receipt of treatment for hepatocellular carcinoma in United States veterans:effect of patient and nonpatient factors[J].Hepatology,2013,57(5):1858-1868.

[5]FORNERA,LLOVET JM,BRUIX J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.

[6]TSUCHIYA N,SAWADA Y,ENDO I,et al.Potentiality of immunotherapy against hepatocellular carcinoma[J].World J Gastroenterol,2015,21(36):10314-10326.

[7]LIN ZX,RUAN DY,LI Y,et al.Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection[J].World J Gastroenterol,2015,21(38):10898-10906.

[8]LEE JH,LIM YS,YEON JE,et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology,2015,148(7):1383-1391.

[9] OHNISHI K,YOSHIOKA H,ITO S,et al.Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma[J].Hepatology,1998,27(1):67-72.

[10]ARIHARA F,MIZUKOSHI E,KITAHARA M,et al.Increase in CD14+HLA-DR-/lowmyeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis[J].Cancer Immunol Immunother,2013,62(8):1421-1430.

[11] BUTTERFIELD LH,RIBAS A,MENG WS,et al.T cell responses to HLA-A*0201 immunodominant peptides derived from alphafetoprotein in patients with hepatocellular cancer[J].Clin Cancer Res,2003,9(16Pt1):5902-5908.

[12]SCHMIDT N,FLECKEN T,THIMME R,et al.Tumor-associated antigen specific CD8+T cells in hepatocellular carcinoma a promising target for immunotherapy[J].Oncoimmunology,2014,3(9):e954919.

[13]HONG YP,LI ZD,ZHANG Q,et al.Immunotherapy for hepatocellular carcinoma:from basic research to clinical use[J].World JHepatol,2015,7(7):980-992.

[14] LI SQ,LIN J,QI CY,et al.GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice[J].Hepatogastroenterology,2014,61(130):278-284.

[15]XU H,GU N,LIU ZB,et al.NY-ESO-1 expression in hepatocellular carcinoma:a potential new marker for early recurrence after surgery[J].Oncol Lett,2012,3(1):39-44.

[16]FLECKEN T,SCHMIDT N,HILD S,et al.Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma[J].Hepatology,2014,59(4):1415-1426.

[17]BUONAGURO L,PETRIZZO A,TAGLIAMONTE M,et al.Challenges in cancer vaccine development for hepatocellular carcinoma[J].JHepatol,2013,59(4):897-903.

[18] LANG J,DING T,GUO ZW,et al.Expression pattern of tumour-associated antigens in hepatocellular carcinoma:association with immune infiltration and disease progression[J].Br J Cancer,2013,109(4):1031-1039.

[19]GEHRING AJ,HO ZZ,TAN AT,et al.Profile of tumor antigenspecific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma[J].Gastroenterology,2009,137(2):682-690.

[20]ZERBINI A,PILLI M,SOLIANI P,et al.Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma[J].J Hepatol,2004,40(1):102-109.

[21]WEON JL,POTTS PR.The MAGE protein family and cancer[J].Curr Opin Cell Biol,2015,37:1-8.

[22]CARULLI L,ANZIVINO C.Telomere and telomerase in chronic liver disease and hepatocarcinoma[J].World J Gastroenterol,2014,20(20):6287-6292.

[23] MIZUKOSHI E,NAKAMOTO Y,MARUKAWA Y,et al.Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma[J].Hepatology,2006,43(6):1284-1294.

[24]MIZUKOSHI E,NAKAGAWA H,KITAHARA M,et al.Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma[J].Cancer Lett,2015,364(2):98-105.

[25] AREF AM,HOA NT,GE L,et al.HCA519/TPX2:a potential T-cell tumor-associated antigen for human hepatocellular carcinoma[J].Onco Targets Ther,2014,7:1061-1070.

[26] JOSEFOWICZ SZ,LU LF,RUDENSKY AY.Regulatory T cells:mechanisms of differentiation and function[J].Annu Rev Immunol,2012,30:531-564.

[27] MOON BI,KIM TH,SEOH JY.Functional Modulation of Regulatory TCells by IL-2[J].PLo S One,2015,10(11):e0141864.

[28]ZHAO HQ,LI WM,LU ZQ,et al.Roles of Tregs in development of hepatocellular carcinoma:a meta-analysis[J].World J Gastroenterol,2014,20(24):7971-7978.

[29]SCHRADER J.The role of MDSCs in hepatocellular carcinoma:in vivo veritas?[J].J Hepatol,2013,59(5):921-923.

[30] ILKOVITCH D,LOPEZ DM.The liver is a site for tumor induced myeloid-derived suppressor cell accumulation and immunosuppression[J].Cancer Res,2009,69(13):5514-5521.

[31]HOECHST B,VOIGTLAENDER T,ORMANDY L,et al.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKP30 receptor[J].Hepatology,2009,50(3):799-807.

[32] MEDINA-ECHEVERZ J,EGGER T,HAN MJ,et al.Hepatic myeloid-derived suppressor cells in cancer[J].Cancer Immunol Immunother,2015,64(8):931-940.

[33]FUJIWARA K,HIGASHI T,NOUSO K,et al.Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma[J].J Gastroenterol Hepatol,2004,19(10):1121-1127.

[34]BERTINO G,DEMMA S,ARDIRI A,et al.Hepatocellular carcinoma:novel molecular targets in carcinogenesis for future therapies[J].Biomed Res Int,2014,2014:203693.

[35] HERBST RS,SORIA JC,KOWANETZ M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature,2014,515(7528):563-567.

[36]ALI MY,GRIMM CF,RITTER M,et al.Activation of dendritic cells by local ablation of hepatocellular carcinoma[J].J Hepatol,2005,43(5):817-822.

施引文献

资源附件(0)

访问统计